|
|
|
| Significance of Prethrombotic State Molecules and Cystatin C Level in Patients with Coronary Heart Disease for Prognosis after Intervention Operation |
| TANG Min, et al |
| Second Affiliated Hospital of Shenyang Medical College, Liaoning Shenyang 110000, China |
|
|
|
|
Abstract Objective: To observe the evaluation significance of prethrombotic state molecules and cystatin C (Cys-C) level in patients with coronary heart disease (CHD) for prognosis after intervention operation. Methods: 72 CHD patients who were admitted to the hospital were enrolled. All underwent percutaneous coronary intervention (PCI). The prethrombotic state molecules [plasma D-dimer (DD), thrombotic precursor protein (TpP), fibrinogen (Fbg), serum von Willebrand factor (vWF)] and Cys-C levels before and at 3d after treatment were compared. They were divided into good prognosis group and poor prognosis group according to follow-up results. The prethrombotic state molecules and Cys-C before and at 3d after treatment were compared between the two groups. Results: The levels of plasma D-D, TpP, Fbg, serum vWF and Cys-C at 3d after PCI were significantly higher than those before treatment (P<0.05). The proportion of patients with diabetes, hyperlipidemia, hypertension and smoking history in poor prognosis group was significantly higher than that in good prognosis group (P<0.05). DD, TpP, Fbg, vWF and Cys-C in both groups at 3d after treatment were significantly higher than those before treatment (P<0.05). At 3d after treatment, D-D, TpP, Fbg, vWF and Cys-C in poor prognosis group were significantly higher than those in good prognosis group (P<0.05). D-D, TpP, Fbg, vWF and Cys-C were independent risk factors for prognosis of patients with CHD after PCI (P<0.05). Conclusion: The levels of prethrombotic state molecules and Cys-C in patients with coronary heart disease have an increasing trend, and the higher the degree of increase, the worse the prognosis of patients, which can be used for prognosis evaluation.
|
|
|
|
|
|
[1] Doshi D,Ben-Yehuda O,Bonafede M,et al.Underutilization of coronary artery disease testing among patients hospitalized with new-onset heart failure[J].Journal of the American College of Cardiology,2016,68(5):450~458.
[2] Roberts J K,Rao S V,Shaw L K,et al.Comparative efficacy of coronary revascularization procedures for multivessel coronary artery disease in patients with chronic kidney disease[J].American Journal of Cardiology,2017,119(9):1344~1351.
[3] 陈洁,崔颖,穆士杰.血栓弹力图与T2DM合并冠心病患者血清铁蛋白的相关性分析[J].中国输血杂志,2016,29(9):929~931.
[4] 刘佳,高洁,马晓娟,等.血栓前状态及血小板聚集率与冠心病危险因素的相关性分析[J].中西医结合心脑血管病杂志,2018,16(5):513~516.
[5] 李霞,程曼丽,纪玉强,等.胱抑素C浓度与冠心病患者冠状动脉病变程度的关系[J].岭南心血管病杂志,2017,23(6):681~684.
[6] Lobo M D,Sobotka P A,Pathak A.Interventional procedures and future drug therapy for hypertension[J].European Heart Journal,2016,38(15):1101.
[7] Zontar D,Kuhelj D,Skrk D,et al.Patient peak skin doses from cardiac interventional procedures.[J].Radiation Protection Dosimetry,2016,139(1~3):262~265.
[8] 钟涛,许伟,胡海亮,等.应用TEG监测冠心病患者的凝血状态及评价抗血小板聚集效果的临床研究[J].中国实验血液学杂志,2018,26(5):1484~1491.
[9] 赵健斌,谭宁,刘勇,等.术前胱抑素C水平对冠脉介入术后急性肾损伤发生和远期不良预后的预测价值[J].实用医学杂志,2016,32(8):1254~1257. |
|
|
|
2019, Vol. 25 
